Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

Status Completed

Clinical Trial Summary

The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.

Clinical Trial Description

This is a Phase IIb/III, randomized, double blinded, decentralized clinical trial evaluating the safety, tolerability, and efficacy of B244 compared to placebo in the treatment of acne vulgaris 1.1. Primary Objectives 1. To evaluate the safety and tolerability of B244 in participants with acne vulgaris 2. To assess the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to week 12 (end of treatment) by: i) Reduction in inflammatory and non-inflammatory lesion count ii) IGA success 3. Improvement in patient reported quality of life score using the Skindex-16 questionnaire in participants with acne vulgaris from baseline to week 12 1.2. Secondary Objectives 1. To evaluate the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to weeks 2, 4, 8, and 16: i) Reduction in inflammatory and non-inflammatory lesion count ii) IGA success iii) Improvement in patient reported quality of life score using the Skindex-16 questionnaire 1.3. Exploratory Objective 1. To evaluate facial skin microbiota in participants with acne vulgaris at baseline, week 4, week 8, week 12, and week 16 in B244-treated participants compared to placebo from: i) Skin swabs will be taken from forehead, nose, both cheeks and chin All participants (placebo and B244) will undergo skin swabs and testing. ;

Study Design

Related Conditions & MeSH terms

Acne Vulgaris

Clinical Trial Details

NCT number	NCT02832063
Study type	Interventional
Source	AOBiome LLC
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	August 2016
Completion date	July 19, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04321070` - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris	Phase 1
Recruiting	`NCT05755256` - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne	Phase 2
Completed	`NCT05131373` - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01445301` - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects	Phase 3
Completed	`NCT03303170` - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris	N/A
Completed	`NCT04698239` - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.	N/A
Completed	`NCT02886715` - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris	Phase 3
Terminated	`NCT02924428` - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris	N/A
Not yet recruiting	`NCT02525822` - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris	Phase 2
Not yet recruiting	`NCT02491060` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Not yet recruiting	`NCT02535871` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Completed	`NCT02709902` - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris	Phase 1
Completed	`NCT02913001` - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne	N/A
Completed	`NCT02250430` - A Phase 1 Study Assessing Local Cutaneous Effects of SB204	Phase 1
Completed	`NCT01694810` - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers	Phase 1
Completed	`NCT01769664` - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01727440` - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment	N/A
Completed	`NCT01194375` - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris	Phase 2
Completed	`NCT01706250` - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™	Phase 4
Completed	`NCT02524665` - 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne	Phase 4